0	5	AM580	AM580	NNP
5	6	,	,	,
7	8	a	a	DT
9	15	stable	stable	JJ
16	23	benzoic	benzoic	JJ
24	34	derivative	derivative	NN
35	37	of	of	IN
38	46	retinoic	retinoic	JJ
47	51	acid	acid	NN
51	52	,	,	,
53	56	has	have	VBZ
57	65	powerful	powerful	JJ
66	69	and	and	CC
70	79	selective	selective	JJ
80	100	cyto-differentiating	cyto-differentiating	JJ
101	108	effects	effect	NNS
109	111	on	on	IN
112	117	acute	acute	JJ
118	131	promyelocytic	promyelocytic	JJ
132	140	leukemia	leukemia	NN
141	146	cells	cell	NNS
146	147	.	.	.

149	158	All-trans	all-trans	JJ
159	167	retinoic	retinoic	JJ
168	172	acid	acid	NN
173	174	(	(	(
174	178	ATRA	ATRA	NNP
178	179	)	)	)
180	182	is	be	VBZ
183	195	successfully	successfully	RB
196	200	used	use	VBN
201	203	in	in	IN
204	207	the	the	DT
208	228	cyto-differentiating	cyto-differentiating	JJ
229	238	treatment	treatment	NN
239	241	of	of	IN
242	247	acute	acute	JJ
248	261	promyelocytic	promyelocytic	JJ
262	270	leukemia	leukemia	NN
271	272	(	(	(
272	275	APL	APL	NNP
275	276	)	)	)
276	277	.	.	.

278	291	Paradoxically	paradoxically	RB
291	292	,	,	,
293	296	APL	APL	NNP
297	302	cells	cell	NNS
303	310	express	express	VBP
311	318	PML-RAR	PML-RAR	NNP
318	319	,	,	,
320	322	an	an	DT
323	331	aberrant	aberrant	JJ
332	336	form	form	NN
337	339	of	of	IN
340	343	the	the	DT
344	352	retinoic	retinoic	JJ
353	357	acid	acid	NN
358	366	receptor	receptor	NN
367	371	type	type	NN
372	377	alpha	alpha	NN
378	379	(	(	(
379	382	RAR	RAR	NNP
383	388	alpha	alpha	NN
388	389	)	)	)
390	397	derived	derive	VBN
398	402	from	from	IN
403	406	the	the	DT
407	424	leukemia-specific	leukemia-specific	JJ
425	433	t(15;17)	t(15;17)	NN
434	445	chromosomal	chromosomal	JJ
446	459	translocation	translocation	NN
459	460	.	.	.

461	463	We	we	PRP
464	468	show	show	VBP
469	473	here	here	RB
474	478	that	that	IN
479	484	AM580	AM580	NNP
484	485	,	,	,
486	487	a	a	DT
488	494	stable	stable	JJ
495	508	retinobenzoic	retinobenzoic	JJ
509	519	derivative	derivative	NN
520	530	originally	originally	RB
531	542	synthesized	synthesize	VBN
543	545	as	as	IN
546	547	a	a	DT
548	551	RAR	RAR	NNP
552	557	alpha	alpha	NN
558	565	agonist	agonist	NN
565	566	,	,	,
567	569	is	be	VBZ
570	571	a	a	DT
572	580	powerful	powerful	JJ
581	588	inducer	inducer	NN
589	591	of	of	IN
592	604	granulocytic	granulocytic	JJ
605	615	maturation	maturation	NN
616	618	in	in	IN
619	622	NB4	NB4	NNP
622	623	,	,	,
624	626	an	an	DT
627	638	APL-derived	apl-derived	JJ
639	643	cell	cell	NN
644	648	line	line	NN
648	649	,	,	,
650	653	and	and	CC
654	656	in	in	IN
657	664	freshly	freshly	RB
665	673	isolated	isolate	VBN
674	677	APL	APL	NNP
678	684	blasts	blast	NNS
684	685	.	.	.

686	691	After	after	IN
692	701	treatment	treatment	NN
702	704	of	of	IN
705	708	APL	APL	NNP
709	714	cells	cell	NNS
715	719	with	with	IN
720	725	AM580	am580	NN
726	732	either	either	CC
733	738	alone	alone	RB
739	741	or	or	CC
742	744	in	in	IN
745	756	combination	combination	NN
757	761	with	with	IN
762	773	granulocyte	granulocyte	NN
774	792	colony-stimulating	colony-stimulating	JJ
793	799	factor	factor	NN
800	801	(	(	(
801	806	G-CSF	G-CSF	NNP
806	807	)	)	)
807	808	,	,	,
809	812	the	the	DT
813	821	compound	compound	NN
822	829	induces	induce	VBZ
830	842	granulocytic	granulocytic	JJ
843	853	maturation	maturation	NN
853	854	,	,	,
855	857	as	as	IN
858	866	assessed	assess	VBN
867	869	by	by	IN
870	883	determination	determination	NN
884	886	of	of	IN
887	890	the	the	DT
891	897	levels	level	NNS
898	900	of	of	IN
901	910	leukocyte	leukocyte	NN
911	919	alkaline	alkaline	NN
920	931	phosphatase	phosphatase	NN
931	932	,	,	,
933	938	CD11b	CD11b	NNP
938	939	,	,	,
940	944	CD33	CD33	NNP
944	945	,	,	,
946	949	and	and	CC
950	955	G-CSF	G-CSF	NNP
956	964	receptor	receptor	NN
965	969	mRNA	mRNA	NNP
969	970	,	,	,
971	973	at	at	IN
974	988	concentrations	concentration	NNS
989	993	that	that	WDT
994	997	are	be	VBP
998	1001	10-	10-	CD
1002	1004	to	to	TO
1005	1013	100-fold	100-fold	RB
1014	1019	lower	low	JJR
1020	1024	than	than	IN
1025	1030	those	those	DT
1031	1033	of	of	IN
1034	1038	ATRA	ATRA	NNP
1039	1048	necessary	necessary	JJ
1049	1051	to	to	TO
1052	1059	produce	produce	VB
1060	1067	similar	similar	JJ
1068	1075	effects	effect	NNS
1075	1076	.	.	.

1077	1079	By	by	IN
1080	1088	contrast	contrast	NN
1088	1089	,	,	,
1090	1095	AM580	AM580	NNP
1096	1098	is	be	VBZ
1099	1102	not	not	RB
1103	1112	effective	effective	JJ
1113	1115	as	as	IN
1116	1120	ATRA	ATRA	NNP
1121	1123	in	in	IN
1124	1134	modulating	modulate	VBG
1135	1138	the	the	DT
1139	1149	expression	expression	NN
1150	1152	of	of	IN
1153	1158	these	these	DT
1159	1174	differentiation	differentiation	NN
1175	1182	markers	marker	NNS
1183	1185	in	in	IN
1186	1189	the	the	DT
1190	1195	HL-60	HL-60	NNP
1196	1200	cell	cell	NN
1201	1205	line	line	NN
1206	1209	and	and	CC
1210	1212	in	in	IN
1213	1220	freshly	freshly	RB
1221	1229	isolated	isolate	VBN
1230	1242	granulocytes	granulocyte	NNS
1243	1251	obtained	obtain	VBN
1252	1256	from	from	IN
1257	1260	the	the	DT
1261	1271	peripheral	peripheral	JJ
1272	1277	blood	blood	NN
1278	1280	of	of	IN
1281	1288	chronic	chronic	JJ
1289	1300	myelogenous	myelogenous	JJ
1301	1309	leukemia	leukemia	NN
1310	1318	patients	patient	NNS
1319	1325	during	during	IN
1326	1329	the	the	DT
1330	1336	stable	stable	JJ
1337	1342	phase	phase	NN
1343	1345	of	of	IN
1346	1349	the	the	DT
1350	1357	disease	disease	NN
1357	1358	.	.	.

1359	1361	In	in	IN
1362	1365	NB4	nb4	NN
1366	1371	cells	cell	NNS
1371	1372	,	,	,
1373	1376	two	two	CD
1377	1382	other	other	JJ
1383	1392	synthetic	synthetic	JJ
1393	1405	nonselective	nonselective	JJ
1406	1409	RAR	rar	NN
1410	1417	ligands	ligand	NNS
1418	1421	are	be	VBP
1422	1429	capable	capable	JJ
1430	1432	of	of	IN
1433	1441	inducing	induce	VBG
1442	1445	LAP	LAP	NNP
1446	1448	as	as	RB
1449	1453	much	much	RB
1454	1456	as	as	IN
1457	1462	AM580	AM580	NNP
1462	1463	,	,	,
1464	1471	whereas	whereas	IN
1472	1475	RAR	rar	NN
1476	1481	beta-	beta-	NN
1482	1484	or	or	CC
1485	1488	RAR	rar	NN
1489	1503	gamma-specific	gamma-specific	JJ
1504	1511	ligands	ligand	NNS
1512	1515	are	be	VBP
1516	1523	totally	totally	RB
1524	1535	ineffective	ineffective	JJ
1535	1536	.	.	.

1537	1542	These	these	DT
1543	1550	results	result	NNS
1551	1555	show	show	VBP
1556	1560	that	that	IN
1561	1566	AM580	am580	NN
1567	1569	is	be	VBZ
1570	1574	more	more	RBR
1575	1583	powerful	powerful	JJ
1584	1588	than	than	IN
1589	1593	ATRA	ATRA	NNP
1594	1596	in	in	IN
1597	1607	modulating	modulate	VBG
1608	1611	the	the	DT
1612	1622	expression	expression	NN
1623	1625	of	of	IN
1626	1641	differentiation	differentiation	NN
1642	1650	antigens	antigen	NNS
1651	1655	only	only	RB
1656	1658	in	in	IN
1659	1664	cells	cell	NNS
1665	1667	in	in	IN
1668	1673	which	which	WDT
1674	1681	PML-RAR	PML-RAR	NNP
1682	1684	is	be	VBZ
1685	1692	present	present	JJ
1692	1693	.	.	.

1694	1701	Binding	binding	NN
1702	1713	experiments	experiment	NNS
1713	1714	,	,	,
1715	1720	using	use	VBG
1721	1726	COS-7	cos-7	NN
1727	1732	cells	cell	NNS
1733	1744	transiently	transiently	RB
1745	1756	transfected	transfecte	VBN
1757	1761	with	with	IN
1762	1769	PML-RAR	PML-RAR	NNP
1770	1773	and	and	CC
1774	1777	the	the	DT
1778	1784	normal	normal	JJ
1785	1788	RAR	rar	NN
1789	1794	alpha	alpha	NN
1794	1795	,	,	,
1796	1800	show	show	VBP
1801	1805	that	that	IN
1806	1811	AM580	AM580	NNP
1812	1815	has	have	VBZ
1816	1817	a	a	DT
1818	1823	lower	low	JJR
1824	1832	affinity	affinity	NN
1833	1837	than	than	IN
1838	1842	ATRA	ATRA	NNP
1843	1846	for	for	IN
1847	1851	both	both	DT
1852	1861	receptors	receptor	NNS
1861	1862	.	.	.

1863	1870	However	however	RB
1870	1871	,	,	,
1872	1874	in	in	IN
1875	1878	the	the	DT
1879	1887	presence	presence	NN
1888	1890	of	of	IN
1891	1898	PML-RAR	PML-RAR	NNP
1898	1899	,	,	,
1900	1903	the	the	DT
1904	1913	synthetic	synthetic	JJ
1914	1922	retinoid	retinoid	NN
1923	1925	is	be	VBZ
1926	1927	a	a	DT
1928	1932	much	much	RB
1933	1939	better	good	JJR
1940	1954	transactivator	transactivator	NN
1955	1957	of	of	IN
1958	1966	retinoic	retinoic	JJ
1967	1982	acid-responsive	acid-responsive	JJ
1983	2001	element-containing	element-containing	JJ
2002	2011	promoters	promoter	NNS
2012	2016	than	than	IN
2017	2020	the	the	DT
2021	2028	natural	natural	JJ
2029	2037	retinoid	retinoid	NN
2037	2038	,	,	,
2039	2046	whereas	whereas	IN
2046	2047	,	,	,
2048	2050	in	in	IN
2051	2054	the	the	DT
2055	2063	presence	presence	NN
2064	2066	of	of	IN
2067	2070	RAR	RAR	NNP
2071	2076	alpha	alpha	NN
2076	2077	,	,	,
2078	2083	AM580	AM580	NNP
2084	2087	and	and	CC
2088	2092	ATRA	ATRA	NNP
2093	2097	have	have	VBP
2098	2105	similar	similar	JJ
2106	2114	activity	activity	NN
2114	2115	.	.	.

2116	2120	This	this	DT
2121	2124	may	may	MD
2125	2132	explain	explain	VB
2133	2136	the	the	DT
2137	2143	strong	strong	JJ
2144	2164	cyto-differentiating	cyto-differentiating	JJ
2165	2174	potential	potential	NN
2175	2177	of	of	IN
2178	2183	AM580	am580	NN
2184	2186	in	in	IN
2187	2205	PML-RAR-containing	pml-rar-containing	JJ
2206	2214	leukemic	leukemic	JJ
2215	2220	cells	cell	NNS
2220	2221	.	.	.